Paracetamol use and risk of ovarian cancer: a meta‐analysis

Bonovas, Stefanos; Filioussi, Kalitsa; Sitaras, Nikolaos M.

doi:10.1111/j.1365-2125.2005.02526.x

Cited by 25 publications

(17 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Acetaminophen use was associated with risk reductions in the order of 30-50% in a meta-analysis [50] and a large Danish data-linkage study [51], although a pooled analysis of 12 case-control studies did not observe an association [52]. The pooled analysis did, however, show that regular aspirin use was associated with a significant 20% reduction in ovarian cancer risk with a similar, but non-significant, reduction for use of other non-steroidal anti-inflammatory drugs (NSAIDs).…”

Section: Non-steroidal Anti-inflammatory Drugsmentioning

confidence: 98%

Epidemiology of epithelial ovarian cancer

Webb

Jordan

2017

Best Practice & Research Clinical Obstetrics & Gynaecol

754

550

View full text Add to dashboard Cite

Globally, ovarian cancer is the seventh most common cancer in women and the eighth most common cause of cancer death, with five-year survival rates below 45%. Although agestandardised rates are stable or falling in most high-income countries, they are rising in many low and middle income countries. Furthermore, with increasing life-expectancy, the number of cases diagnosed each year is increasing. To control ovarian cancer we need to understand the causes. This will allow better prediction of those at greatest risk for whom screening might be appropriate, while identification of potentially modifable causes provides an opportunity for intervention to reduce rates. In this paper we will summarise the current state of knowledge regarding the known and possible causes of epithelial ovarian cancer and discuss some of the main theories of ovarian carcinogenesis. We will also briefly review the relationship between lifestyle and survival after a diagnosis of ovarian cancer.[Words=148] KEY WORDSOvarian neoplasms; epidemiology; incidence; risk factors; survival M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 3 INTRODUCTIONGlobally, 240,000 women are diagnosed with ovarian cancer every year and, with five-year survival below 45%, it is responsible for 150,00 deaths making it the 7 th most common cancer and 8 th most common cause of cancer death among women [1]. Figure 1A shows that agestandardised incidence rates are highest in northern and central/eastern Europe, intermediate in north America, Australia and western Europe and lowest in Asia and Africa. Rates have been decreasing in most high incidence countries but increasing in many low incidence countries ( Figure 1B) thus the differences today are less marked than 30 years ago [2]. Rates also vary by ethnicity within countries such that in the United States, rates in non-Hispanic white women are approximately 30% higher than African-American and Asian women and 12% higher than Hispanic women [3].

Ovarian cancer is rare in women under 40 years of age and most cancers in this age group are germ cell tumours. Above age 40, more than 90% are epithelial tumours and the risk increases with age, peaking in the late 70s. Despite being classified as ovarian, a high proportion of highgrade serous cancers are now thought to originate from the fallopian tube. In the following discussion the term 'ovarian cancer' refers to epithelial cancers that arise in the ovary or fallopian tube as well as the histologically similar primary peritoneal cancers. RISK FACTORSIt is well established that women with a family history of ovarian cancer are themselves at higher risk of the disease. The risk for women with one affected first-degree relative is about three times that for women with no affected relatives [4], and even higher for those whose M A N U S C R I P T A C C E P T E D The following sections review non-genetic factors known or suspected to affect a woman's risk of developing epithelial ovarian cancer, with most weight given to recent meta-...

show abstract

Section: Non-steroidal Anti-inflammatory Drugsmentioning

confidence: 98%

Epidemiology of epithelial ovarian cancer

Webb

Jordan

2017

Best Practice & Research Clinical Obstetrics & Gynaecol

754

550

View full text Add to dashboard Cite

show abstract

“…Previous publications have provided mixed opinions on whether quality scoring should be used as a weighting variable. Some articles comment that quality scoring adds subjective bias and may lack validity, and results may not represent quality (Bonovas, Filioussi, & Sitaras, 2006;Greenland, 1994;Juni, Witschi, Bloch, & Egger, 1999;Stroup et al, 2000). Other studies claim that quality scoring can be done but recommend not using the scores as weights but rather using the summary score as a covariate to conduct subgroup and sensitivity analysis (Berman & Parker, 2002;Friedenreich, Brant, & Riboli, 1994;Stroup et al, 2000).…”

Section: Discussionmentioning

confidence: 99%

Do African American Men Have Lower Survival From Prostate Cancer Compared With White Men? A Meta-analysis

et al. 2010

View full text Add to dashboard Cite

Prostate cancer is the second leading cause of cancer-related mortality in men. This meta-analysis was conducted to investigate the relationship between race and survival from prostate cancer. A systematic review of articles published from 1968 to 2007 assessing survival from prostate cancer was conducted. Analysis of unadjusted studies reported that African American men have an increased risk of all-cause mortality (hazard ratio [HR] = 1.47, 95% confidence interval [CI] = 1.31-1.65, p < .001). However, examination of adjusted studies identified no difference (HR = 1.07, 95% CI = 0.94-1.22, p = .308). No statistically significant difference was observed in prostate cancer-specific survival in both analyses using unadjusted (HR = 1.11, 95% CI = 0.94-1.31, p = .209) and adjusted studies (HR = 1.15, 95% CI = 0.95-1.41, p = .157). This meta-analysis concludes that there are no racial differences in the overall and prostate cancer-specific survival between African American and White men.

show abstract

“…Les résul-tats visant à établir un lien entre prise de paracétamol et incidence du cancer de l'ovaire ont récemment été passés en revue [37]. Cette méta-analyse de huit études réalisées entre 1998 et 2004 montre une réduction de 30 % du risque de survenue d'un cancer de l'ovaire en cas de prise régulière de paracétamol (30 prises par mois sur au moins six mois, dans la plupart des études).…”

Section: Prise De Médicamentsunclassified